[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hepatopancreatobiliary Surgery Institute of Gansu Province\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":162},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,83,109,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100652310","bao-yuan-tang-extract-and-galactooligosaccharides-for-sleep-regulation-100652310",false,"NCT07774897","Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation","Sleep-Promoting Effects of Bao Yuan Tang Whole-Component Extract Combined With Galactooligosaccharides: A Prospective, Multicenter, Triple-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Female registered nurses aged 25-45 years.\n* Participants must meet at least one of the following criteria, self-reported presence of at least one target symptom of the trial, including insomnia, daytime fatigue, or difficulty initiating sleep or Pittsburgh Sleep Quality Index (PSQI) score \\>7.\n* Engagement in shift work for at least one month before enrollment, with either ≥ 4 night shifts or ≥32 hours of night-shift work during the preceding month.\n\nExclusion Criteria:\n\n* Diagnosed with type 1 or type 2 diabetes mellitus and currently receiving pharmacological treatment.\n* Diagnosed with clinically thyroid dysfunction, including hyperthyroidism or hypothyroidism, and currently receiving pharmacological treatment.\n* Diagnosed with Cushing's syndrome, pituitary dysfunction, or other clearly defined endocrine disorders.\n* Diagnosed with polycystic ovary syndrome (PCOS) and currently receiving pharmacological treatment.\n* Use of medications that may affect study outcomes, including oral contraceptives, glucose-lowering agents, hormonal medications, hypnotics, lipid-regulating agents, or thyroid hormone preparations, within the past 3 months.\n* Pregnancy, lactation, or planned pregnancy during the study period.\n* Confirmed severe organic diseases, such as hepatic or renal insufficiency, cardiovascular disease, or malignancy.\n* Known allergy to any component of the investigational product.\n* Use of probiotics, prebiotics, or related traditional Chinese medicine preparations within the past 1 month.\n* Participation in another clinical trial within the past 3 months.\n* Planned engagement in vigorous exercise or a weight-management program during the study period.\n* A previous diagnosis of psychiatric disorders, such as anxiety or depression.\n* Any condition judged by the investigator to involve communication difficulties, poor compliance, or potential interference with adherence to the study protocol.",true,"FEMALE","25 Years","45 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Certain classical formulas in traditional Chinese medicine and dietary prebiotics have demonstrated beneficial effects on various aspects of suboptimal health status in previous studies. This research aims to evaluate the effects of Bao Yuan Tang full-component extract combined with galactooligosaccharides on improving health-related outcomes in female registered nurse with suboptimal health status, including sleep disturbances, fatigue, endocrine dysregulation, and glucose and lipid metabolic abnormalities.",[28,29,30,31,32],"Sleep Disturbance","Fatigue Syndrome, Chronic","Endocrine Disorder","Glucose Metabolism Disorder","Lipid Metabolism Disorders",[34,35,36,37,38],"Bao Yuan Tang full-component extract","Galactooligosaccharides","Sleep quality","Prebiotic","Metabolic health","NOT_YET_RECRUITING","2026-08-16",{"date":42,"type":43},"2026-08-19","ACTUAL",{"date":45,"type":22},"2026-09-30",{"date":47,"type":22},"2027-09-30",{"name":49,"class":50},"Hepatopancreatobiliary Surgery Institute of Gansu Province","OTHER",6,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":5},"100617654","the-optimal-measurement-time-for-the-new-gallbladder-function-assessment-method-100617654","NCT07321431","The Optimal Measurement Time for the New Gallbladder Function Assessment Method","The Optimal Measurement Time for the New Gallbladder Function Assessment Method: A Prospective, Multicenter, Double-Blind, Crossover Trial","Inclusion Criteria:\n\n* Ultrasound assessment identifies people with normal biliary tract structure.\n\nExclusion Criteria:\n\n* History of Endoscopic Retrograde Cholangiopancreatography\n* Previous gallstone removal surgery with gallbladder preservation\n* Other biliary tract diseases and related surgical history\n* History of acute or chronic pancreatitis\n* History of gastrointestinal surgery\n* Gastrointestinal obstruction\n* Dysfunction of the sphincter of Oddi\n* Gallbladder neck polyps\n* Abnormal gallbladder structure\n* Gallbladder mass\n* Biliary infection or stones\n* Congenital biliary abnormalities\n* Biliary injury or surgery\n* Biliary tumors\n* Gastrointestinal bleeding, liver cirrhosis, or other malignant diseases\n* Significant arrhythmia, bradycardia, or atrioventricular block\n* Severe hypertension, liver or kidney insufficiency\n* Immune, endocrine, hematological, or mental disorders\n* Severe cerebrovascular disease\n* Allergy to relevant foods\n* Pregnant or breastfeeding women\n* Unwillingness or inability to consent to participation","ALL","18 Years","70 Years",{"count":63,"type":22},120,[25],"This is a multicenter, prospective, randomized, double-blind, crossover study involving healthy individuals, aiming to evaluate the stability of oral protein bars + olive oil as a new method for determining gallbladder contraction function and its optimal diagnostic time window.",[67],"Gallbladder; Functional Disturbance",[69,70,71,72,73],"Gallbladder Contractile Function","Ultrasound Examination","Olive oil","Protein Bar","Optimal time","RECRUITING","2026-01-06",{"date":77,"type":43},"2026-01-08",{"date":79,"type":43},"2026-01-07",{"date":81,"type":22},"2026-12-20",{"name":49,"class":50},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100569806","a-strategy-for-gallstone-expulsion-through-dietary-therapy-100569806","NCT06699030","A Strategy for Gallstone Expulsion Through Dietary Therapy","A New Strategy for Gallstone Expulsion Through Dietary Therapy: A Prospective, Single-Center, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Gallbladder sludge-like stones with a maximum stone diameter of less than 2 mm\n\nExclusion Criteria:\n\n* History of ERCP (Endoscopic Retrograde Cholangiopancreatography)\n* Previous gallstone removal surgery with gallbladder preservation\n* History of acute or chronic pancreatitis, cholangitis\n* Mirizzi Syndrome\n* History of gastrointestinal surgery\n* Gastrointestinal obstruction\n* Dysfunction of the sphincter of Oddi\n* Gallbladder neck polyps\n* Abnormal gallbladder structure\n* Gallbladder mass\n* Biliary infection or stones\n* Congenital biliary abnormalities\n* Biliary injury or surgery\n* Biliary tumors\n* Gastrointestinal bleeding, liver cirrhosis, or other malignant diseases\n* Significant arrhythmia, bradycardia, or atrioventricular block\n* Severe hypertension, liver or kidney insufficiency\n* Immune, endocrine, hematological, or mental disorders\n* Severe cerebrovascular disease\n* Allergy to relevant foods\n* Pregnant or breastfeeding women\n* Unwillingness or inability to consent to participation",{"count":91,"type":22},100,[25],"This study is a double-blind, prospective, single-center controlled trial conducted at a tertiary hospital, aiming to determine whether dietary therapy can effectively expel gallstones.",[95],"Gallbladder Stone",[97,98,99,70],"Gallstone","Gallbladder Function","Cholecystitis","2025-12-24",{"date":102,"type":43},"2025-12-31",{"date":104,"type":43},"2024-12-24",{"date":106,"type":22},"2026-12-01",{"name":49,"class":50},1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100293799","effect-of-37-non-ionic-contrast-agent-during-ercp-procedure-in-hilar-cholangiocarcinoma-100293799","NCT03104569","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;\n* Age: 18\\~90 years old;\n* Underwent diagnostic and therapeutic ERCP;\n\nExclusion Criteria:\n\n* Coagulation dysfunction(INR\\>1.3) or\u002Fand low peripheral blood platelet count （PLT \\\u003C50x10\\^9\u002FL）;\n* Preoperative acute cholangitis;\n* Preoperative acute pancreatitis;\n* Preoperative hemobilia or hemorrhage of digestive tract;\n* Preoperative liver failure;\n* Combined with Mirizzi syndrome and intrahepatic bile duct stones;\n* Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas, gallbladder carcinoma;\n* Biliary-duodenal fistula confirmed during ERCP;\n* A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a history of cholangioenterostomy including cholangio-jejunostomy and side to side anastomosis of the bile duct and duodenum;\n* Previous ERCP;\n* Pregnant women","90 Years",{"count":91,"type":22},[25],"The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.",[121],"Cholangitis",[123,124,125,121,126],"ERCP","Contrast agent","Hilar cholangiocarcinoma","Nonionic","2025-12-19",{"date":129,"type":43},"2025-12-26",{"date":131,"type":22},"2026-04-01",{"date":133,"type":22},"2028-12-01",{"name":49,"class":50},3,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":108},"100599979","whether-control-of-serum-uric-acid-sua-improves-survival-after-pancreatic-cancer-100599979","NCT07091526","Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer","Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed pancreatic cancer (primary)\n* Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）\n* The postoperative survival time was at least 6 weeks\n\nExclusion Criteria:\n\n* No surgery was performed, or only palliative surgery\u002F biopsy was performed\n* Patients who underwent emergency hemodialysis or plasma exchange after surgery\n* History of gout or long-term urate-lowering therapy, such as allopurinol\n* Patients are missing follow-up data\n* Hydrochlorothiazide and furosemide were used\n* Chronic kidney disease\n* Oncolytic syndrome\n* Hemolytic anemia\n* Lead poisoning\n* Hyperparathyroidism\n* Hypothyroidism\n* A tyrosinase inhibitor was used\n* Patients with nonpancreatic primary tumors\n* Pregnant or postpartum women.","85 Years",{"count":145,"type":22},168,"OBSERVATIONAL","This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.",[149],"Serum Uric Acid",[151,152,153,154],"Serum uric acid","Pancreatic cancer","Pancreaticoduodenectomy","Distal pancreatectomy","2025-12-13",{"date":127,"type":43},{"date":158,"type":43},"2025-07-29",{"date":160,"type":22},"2026-12-29",{"name":49,"class":50},""]